IBD Medication and management, questionnaire responses
| Question (no of responders) | Responses | Frequency (%) |
| Current medications for treatment of IBD | Prednisolone | 10.5 |
| Topical steroids | 4.2 | |
| 5 ASA | 41 | |
| Thiopurines | 35.9 | |
| Methotrexate | 6.8 | |
| Anti-TNF | 32.8 | |
| Ustekinumab | 7.6 | |
| Vedolizumab | 13 | |
| Tofacitinib | 0.3 | |
| Study drugs (clinical trials) | 0.8 | |
| Symptom control medication | 21.5 | |
| IBD medication knowledge (n=336) | Very high level | 11.9 |
| High Level | 39.9 | |
| Intermediate | 36.6 | |
| Low level | 9.5 | |
| Very low level | 2.1 | |
| IBD medication adherence pre-COVID-19 pandemic (n=328) | Rarely missed a dose | 79.3 |
| Occasionally missed a dose | 17.4 | |
| Frequently missed a dose | 3.4 | |
| IBD follow-up (n=334) | Public IBD Clinic | 26.3 |
| Public gastroenterology clinic | 15.3 | |
| Public surgical clinic | 1.2 | |
| Private gastroenterologist | 50 | |
| Private surgeon | 0.3 | |
| General practitioner | 6.9 | |
| Access to IBD nurse (n=335) | Yes | 46.9 |
| Access to phone based gastroenterology service (n=335) | Yes | 67.5 |
| Advice received on reducing COVID-19 infection risk (n=335) | Yes | 53.1 |
| Perceived usefulness of the advice (n=177) | Extremely useful | 27.7 |
| Very useful | 43.5 | |
| Somewhat useful | 26.0 | |
| Not so useful | 2.8 | |
| Not at all useful | 0 | |
| Place of presentation in event of significant IBD flare assuming no pandemic (n=328) | Emergency department | 20.7 |
| Gastroenterologist | 43.9 | |
| General practitioner | 18.6 | |
| Self-medicate | 5.2 | |
| IBD helpline/IBD nurse | 11.6 | |
| Place of presentation in event of significant IBD flare during COVID-19 pandemic (n=326) | Emergency department | 19.3 |
| Gastroenterologist | 44.2 | |
| General practitioner | 14.7 | |
| Self-medicate | 7.4 | |
| IBD helpline/IBD nurse | 14.4 | |
| Ceased IBD medications due to COVID-19 pandemic (n=326) | Yes, on own accord | 1.8 |
| Yes, on health professional advice | 3.4 | |
| No | 94.8 | |
| Advised by a health provider to stop IBD medication due to COVID-19 | Gastroenterologist | 4.0 |
| Surgeon | 0.6 | |
| GP | 3.1 | |
| Allied health professional | 0.6 | |
| Alternative therapy practitioner | 2.3 |
ASA, Aminosalicylic acid; GP, general practitioner; IBD, inflammatory bowel disease; TNF, tumour necrosis factor.